Data gathered: December 26
Alternative Data for Gain Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | 8 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,617 | Sign up | Sign up | Sign up |
| Twitter Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Gain Therapeutics
Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is headquartered in Bethesda, Maryland.
| Price | $1.62 |
| Target Price | Sign up |
| Volume | 83,690 |
| Market Cap | $42M |
| Year Range | $0.94 - $3.39 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Roth Mkm Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX)December 25 - ETF Daily News |
 |
Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKMDecember 25 - Yahoo Entertainment |
|
Gain Therapeutics (NASDAQ:GANX) Initiates Phase 1b Clinical Trial for GT-02287 in AustraliaDecember 24 - ETF Daily News |
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s DiseaseDecember 23 - GlobeNewswire |
|
Gain Therapeutics To Present At Biotech Showcase 2025December 11 - GlobeNewswire |
|
 |
Gain Therapeutics (NASDAQ:GANX) Earns Buy Rating from Analysts at Roth MkmDecember 8 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 1.8M | -1.9M | -4.5M | 0 | 0.000 |
| Q2 '24 | 41,000 | 3.7M | -3.7M | -8.1M | 0 | -0.420 |
| Q1 '24 | 380,000 | 1.9M | -1.5M | -4M | 0 | -0.220 |
| Q4 '23 | 0 | 2M | -2M | -4.7M | 0 | -0.360 |
| Q3 '23 | 0 | 2.5M | -2.3M | -4.7M | 0 | -0.370 |
Insider Transactions View All
| Islam Khalid filed to buy 50,000 shares at $1. August 12 '24 |
| Mack Gene filed to buy 14,400 shares at $1. August 12 '24 |
| RICHMAN ERIC I filed to buy 277,629 shares at $1.2. July 1 '24 |
| RICHMAN ERIC I filed to buy 289,629 shares at $1.2. July 1 '24 |
| Riley Jeffrey Scott filed to buy 30,000 shares at $3.9. April 1 '24 |
Similar companies
Read more about Gain Therapeutics (GANX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Gain Therapeutics?
The Market Cap of Gain Therapeutics is $42M.
What is the current stock price of Gain Therapeutics?
Currently, the price of one share of Gain Therapeutics stock is $1.62.
How can I analyze the GANX stock price chart for investment decisions?
The GANX stock price chart above provides a comprehensive visual representation of Gain Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gain Therapeutics shares. Our platform offers an up-to-date GANX stock price chart, along with technical data analysis and alternative data insights.
Does GANX offer dividends to its shareholders?
As of our latest update, Gain Therapeutics (GANX) does not offer dividends to its shareholders. Investors interested in Gain Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Gain Therapeutics?
Some of the similar stocks of Gain Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.